Lu Si, Xiaoshi Zhang , Sang Joon Shin , Yun Fan , Chia-Chi Lin , Tae Min Kim, Arunee Dechaphunkul , Jedzada Maneechavakajorn , Chi Sing Wong , Palanichamy Ilankumaran, Dung-Yang Lee , Eduard Gasal , Haifu Li, Jun Guo*.Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma,Eur J Cancer,2020 Jun 10;135:31-38

Wei X, Wu D, Li H, et al. The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma,Ann Surg Oncol,2020 Apr 6.

Wei X, Si L, Guo J. ASO Author Reflections: Primary Site Should Be Regarded as One Important Factor for Risk Stratification in Acral Melanoma,Ann Surg Oncol,2020 Apr 4

Si L, Zhang X, Shu Y, et al. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151),Transl Oncol,2019 Jun;12(6):828-835

Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study,Oncol Res.,2019 Mar 29;27(4):495-501.

中国临床肿瘤学会黑色素瘤诊疗指南-2019版, 参编, 人民卫生出版社, 2019.7

《肿瘤疾病诊疗规范精解》黑色素瘤分册, 参编, 中国协和医科大学出版社, 2019.11

黑色素瘤靶向及免疫治疗

黑色素瘤精准治疗模式探索